Preprocorticotropin releasing hormone: cDNA sequence and in vitro processing

  title={Preprocorticotropin releasing hormone: cDNA sequence and in vitro processing},
  author={Bruce G. Robinson and L. A. D'Angio and K B Pasieka and Joseph A. Majzoub},
  journal={Molecular and Cellular Endocrinology},

Processing of procorticotropin-releasing hormone (pro-CRH): molecular forms of CRH in normal and preeclamptic pregnancy.

The studies using maternal plasma indicate that CRH(1-41) is the only one of the pro-CRH fragments studied to be maintained in significant amounts in the maternal circulation and also the only fragment studied for which a specific plasma binding protein exists.

Second messenger regulation of mRNA for corticotropin-releasing factor.

In vitro studies of glucocorticoid negative regulation and second messengers and their ligands coupled to CRF gene activation suggest that this effect involves binding of the receptor to the CRF promoter.

Nitric oxide inhibits corticotropin-releasing hormone exocytosis but not synthesis by cultured human trophoblasts.

The studies indicate that exogenous NO inhibits CRH exocytosis, rather than biosynthesis, by human trophoblasts and that endogenous NO has tonic inhibitory effects on CRH release by these cells.

Corticotrophin releasing hormone levels in human plasma and amniotic fluid during gestation

It is confirmed that third trimester plasma levels of corticotrophin releasing hormone are increased in patients with pregnancy‐induced hypertension compared to normotensives, and the recovery of extracted corticotin releasing hormone from plasma and amniotic fluid is increased.

Protein kinase-C activation increases the quantity and poly(A) tail length of corticotropin-releasing hormone messenger RNA in NPLC cells.

The ability of TPA to increase CRH mRNA levels in NPLC cells suggests that the protein kinase-C second messenger pathway may be involved in the physiological regulation of CRH gene expression.



Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta.

Corticotropin-releasing hormone (CRH), a hypothalamic neuropeptide involved in the regulation of ACTH secretion, has been detected by RIA in extracts of human placenta. We wished to determine whether

The corticotropin releasing hormone gene is expressed in human placenta.

Isolation and sequence analysis of the human corticotropin‐releasing factor precursor gene.

The deduced amino acid sequence of human corticotropin‐releasing factor exhibits seven amino acid substitutions in comparison with the ovine counterpart.

Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion.

The availability of synthetic replicates of ovineCRF and rat/human CRF and the production of antisera or antagonists directed against these entities have allowed experiments that have increased understanding of the mechanisms that regulate the function of the corticotroph, and established CRF as a major physiologic regulator of ACTH secretion.

Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta

Using a monolayer primary culture of human placental cells, it is found that CRF stimulates secretion of peptides containing the ACTH sequence in the placenta in a dose-dependent manner, as it does in the pituitary.

High levels of corticotropin-releasing hormone immunoactivity in maternal and fetal plasma during pregnancy.

It is concluded that a large amount of CRHi is secreted by the placenta into both the maternal and fetal circulation during pregnancy and suggest that this may be an important modulator of the mothers and fetal hypothalamic-pituitary-adrenal axis during gestation.

Effects of adrenalectomy and dexamethasone administration on the level of prepro-corticotropin-releasing factor messenger ribonucleic acid (mRNA) in the hypothalamus and adrenocorticotropin/beta-lipotropin precursor mRNA in the pituitary in rats.

The results suggest that glucocorticoids exert their feedback effect at the level of gene expression on both hypothalamic CRF neurons and pituitary corticotropes.

Immunoreactive corticotropin-releasing factor is present in human maternal plasma during the third trimester of pregnancy.

The detection of IR CRF exclusively in third trimester maternal plasma is detected, together with the previous demonstration that material physicochemically indistinguishable from it is present in human term placental e...

Measurement of circulating corticotrophin-releasing factor in man.

In normal subjects no changes in plasma CRF-41 occurred after insulin-induced hypoglycaemia, treatment with dexamethasone or feeding, and changes in the concentrations did not reflect circadianChanges in plasma concentrations of cortisol.